Free Submission Public Relations &
Deutsch English


Just Released: "Trelstar (Prostate Cancer) - Forecast and Market Analysis to 2022"

Print article Print article
2013-03-03 11:07:46 - New Pharmaceuticals market report from GlobalData: "Trelstar (Prostate Cancer) - Forecast and Market Analysis to 2022"

GlobalData has released its new PharmaPoint Drug Evaluation report, "Trelstar (Prostate Cancer) - Forecast and Market Analysis to 2022". The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naive mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer,

androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Full Report Details at
- ..

Trelstar was initially developed by the Debiopharm Group, which in-licensed the drug from Tulane University. It is currently marketed under different names by a number of partners, including Watson (Trelstar, US), Ipsen (Decapeptyl, 5EU; Diphereline, Australia), and Paladin labs (Trelstar, Canada). Trelstar is an LHRH agonist used to achieve castrate levels of testosterone in men with advanced prostate cancer. It can be used with or without antiandrogen co-treatment, and in patients with both hormone-sensitive and castration-resistant disease. Like all LHRH agonists, including Abbott's Lupron Depot, AstraZeneca's Zoladex, and Sanofi's Eligard, Trelstar acts by binding to the LHRH receptor, and prevents the pituitary gland from secreting luteinizing hormone.


* Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Trelstar including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Trelstar for the top nine countries from 2012 to 2022.
* Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Trelstar performance
* Obtain sales forecast for Trelstar from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.2.1 Conservative Management Strategies
4.2.2 Localized Treatments
4.2.3 Hormone Therapy
4.2.4 Drug Therapies
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Trelstar (triptorelin acetate)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment
7.4.2 Percent Drug-treated Patients
7.4.3 Percent Hormone Therapy-Treated Patients
7.4.4 General Pricing Assumptions
7.4.5 Individual Drug Assumptions
7.4.6 Generic Erosion
7.5 Physicians and Specialists Included in This Study
7.6 Survey of Prescribing Physicians
7.7 About the Authors
7.7.1 Authors
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Contact Us
7.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets
Table 2: Global Variations in Recommendations on Routine PSA Screening
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012
Table 5: Leading Treatments for Prostate Cancer, 2012
Table 6: Product Profile - Trelstar
Table 7: Trelstar SWOT Analysis, 2012
Table 8: Global Sales Forecasts ($m) for Trelstar, 2012-2022
Table 9: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact